Keat Hong Lee1, Myat Oo Aung2, Seng Gee Lim3,4,5. 1. Department of Gastroenterology and Hepatology, National University Hospital, National University Health System, 1E Lower Kent Ridge Road, Tower Block, Level 10, Buona Vista, 119228, Singapore. keat_hong_lee@nuhs.edu.sg. 2. Department of Gastroenterology and Hepatology, National University Hospital, National University Health System, 1E Lower Kent Ridge Road, Tower Block, Level 10, Buona Vista, 119228, Singapore. myat_oo_aung@nuhs.edu.sg. 3. Department of Gastroenterology and Hepatology, National University Hospital, National University Health System, 1E Lower Kent Ridge Road, Tower Block, Level 10, Buona Vista, 119228, Singapore. seng_gee_lim@nuhs.edu.sg. 4. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Buona Vista, Singapore. seng_gee_lim@nuhs.edu.sg. 5. Department of Gastroenterology and Hepatology, National University Hospital, 5 Lower Kent Ridge Road, Buona Vista, 119074, Singapore. seng_gee_lim@nuhs.edu.sg.
Abstract
PURPOSE: Practice guidelines for chronic hepatitis B (CHB) assist physicians in management; however, there are also areas where they provide no guidance. This paper aimed to examine treatment preferences for CHB among physicians based upon the Asia Pacific Association for the Study of the Liver (APASL) consensus guidelines 2008. METHODS: A questionnaire was prepared consisting of 18 questions grouped into 8 sections: basic information of participants, the proportion and number of CHB patients on treatment, case scenarios of treatment initiation, preferences for antiviral therapy, scenarios for stopping and continuing antiviral therapy, monitoring patients during therapy, and viral resistance management. The questionnaire was introduced to the APASL 2009 conference delegates. RESULTS: A total of 508 participants from 34 countries participated in the survey. Lamivudine or peg-interferon monotherapy was the preferred first-line therapy, while lamivudine/adefovir combination was the drug of choice for rescue therapy. Drug efficacy and cost were the most important factors to consider before initiating treatment, while viral resistance had a low priority. In general, the APASL guideline was strictly followed in about 50-60 % of the scenarios (initiating, stopping, or continuing antiviral therapy). CONCLUSIONS: The survey concluded that clinical management preferences differed from APASL guidelines in many instances.
PURPOSE: Practice guidelines for chronic hepatitis B (CHB) assist physicians in management; however, there are also areas where they provide no guidance. This paper aimed to examine treatment preferences for CHB among physicians based upon the Asia Pacific Association for the Study of the Liver (APASL) consensus guidelines 2008. METHODS: A questionnaire was prepared consisting of 18 questions grouped into 8 sections: basic information of participants, the proportion and number of CHB patients on treatment, case scenarios of treatment initiation, preferences for antiviral therapy, scenarios for stopping and continuing antiviral therapy, monitoring patients during therapy, and viral resistance management. The questionnaire was introduced to the APASL 2009 conference delegates. RESULTS: A total of 508 participants from 34 countries participated in the survey. Lamivudine or peg-interferon monotherapy was the preferred first-line therapy, while lamivudine/adefovir combination was the drug of choice for rescue therapy. Drug efficacy and cost were the most important factors to consider before initiating treatment, while viral resistance had a low priority. In general, the APASL guideline was strictly followed in about 50-60 % of the scenarios (initiating, stopping, or continuing antiviral therapy). CONCLUSIONS: The survey concluded that clinical management preferences differed from APASL guidelines in many instances.
Authors: Gang Chen; Wenyao Lin; Fumin Shen; Uchenna H Iloeje; W Thomas London; Alison A Evans Journal: Int J Epidemiol Date: 2005-01-19 Impact factor: 7.196
Authors: Joseph J Y Sung; Deepak Amarapurkar; Henry L Y Chan; Jun Cheng; Jia-Horng Kao; Kwang-Hyub Han; Teerha Piratvisuth Journal: Antivir Ther Date: 2010
Authors: Siwaporn Chainuvati; Jun Cheng; Jin Lin Hou; Chao Wei Hsu; Ji Dong Jia; Piyawat Komolmit; So Young Kwon; Chang Hong Lee; Hong Li; Ying Li; Chun Jen Liu; Boon Leong Neo; Cheng Yuan Peng; Tawesak Tanwandee; Suchat Wongcharatrawee; Jaw Ching Wu; Ming Lung Yu; Xin Xin Zhang Journal: Hepatol Int Date: 2009-06-24 Impact factor: 6.047
Authors: Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Jean-Michel Pawlotsky; Geoffrey Dusheiko; Angelos Hatzakis; Daryl Lau; George Lau; T Jake Liang; Stephen Locarnini; Paul Martin; Douglas D Richman; Fabien Zoulim Journal: Gastroenterology Date: 2007-11-28 Impact factor: 22.682
Authors: Man-Fung Yuen; Wai-Kay Seto; Danny Hoi-Fan Chow; Kit Tsui; Danny Ka-Ho Wong; Vincent Wing-Shun Ngai; Benjamin Chun-Yu Wong; James Fung; John Chi-Hang Yuen; Ching-Lung Lai Journal: Antivir Ther Date: 2007
Authors: Seng Gee Lim; Deepak N Amarapurkar; Henry Lik-Yuen Chan; Darrell H Crawford; Edward J Gane; Kwang-Hyub Han; Sang Hoon Ahn; Wasim Jafri; Jidong Jia; Jia-Horng Kao; Laurentius A Lesmana; C Rinaldi A Lesmana; Rosmawati Mohamed; Pham Hoang Phiet; Teerha Piratvisuth; Shiv K Sarin; Jose D Sollarno; Yuichiro Eguchi; Mamun-Al Mahtab; Keat Hong Lee Journal: Hepatol Int Date: 2014-12-11 Impact factor: 6.047